Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) Starts Presentation at 29th Annual ROTH Conference
Eleven Biotherapeutics (NASDAQ: EBIO) is a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based upon the company's targeted protein therapeutics (TPTs) platform. The company's TPTs incorporate a tumor-targeting antibody fragment and a protein cytotoxic payload into a single protein molecule in order to achieve focused tumor cell killing. The company believes its TPTs provide effective tumor targeting with broader cancer cell-killing properties than are achievable with small molecule payloads that require tumor cell proliferation and face multi-drug resistance mechanisms. Additionally, the company believes that its TPT's cancer cell-killing properties promote an anti-tumor immune response that…
